Analyst Craig Hettenbach of Morgan Stanley maintained a Buy rating on Lifestance Health Group, with a price target of $10.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Craig Hettenbach has given his Buy rating due to a combination of factors tied to LifeStance’s improving fundamentals and execution. He highlights that better utilization of clinicians, reflected in faster visit growth than clinician headcount, has already contributed to revenue outperformance and could remain a key driver into 2026, especially as management focuses on sustaining fuller schedules.
He also emphasizes the firm’s stronger operating framework, consistent organic expansion, and rising free cash flow, which together provide capacity for value-accretive tuck-in acquisitions. In addition, ongoing technology and AI initiatives, along with strategic partnerships such as the Calm collaboration, are expected to boost productivity, broaden the patient funnel, and enhance long-term growth, supporting the favorable risk‑reward that underpins his Buy view.
According to TipRanks, Hettenbach is a 3-star analyst with an average return of 2.6% and a 52.98% success rate.